Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease

NCT01977781 ↗

Phase 1 Completed 40 enrolled Massachusetts Eye and Ear Infirmary

RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of topical tacrolimus 0.05% twice a day in the treatment of ocular graft versus host disease (GVHD).

Timeline

Start: 2013-12
Primary completion: 2014-09
Completion: 2014-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Methylprednisolone	Other / unclassified	0.5 %	Topical
Subject	Tacrolimus	Small molecule	0.05 %	Topical

Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease

Summary

Timeline

Drugs

Indications